Abstract
Cognitive Behavioral Therapy (CBT) is an established adjunctive treatment for schizophrenia with a growing evidence base. More recently, CBT has been applied to individuals identified as being at risk for developing psychosis in an attempt to delay or prevent a transition to psychosis, to reduce symptoms and improve functioning. CBT has also been employed effectively with adolescents in the treatment of depression, post traumatic stress disorder (PTSD), anxiety disorders and eating disorders. This paper reviews the evidence for the use of CBT with the clinical high risk for psychosis population and addresses adaptations to the approach for use specifically with adolescents.
Keywords: Adolescents, clinical high risk, cognitive behavioral therapy, psychosis, psychosocial interventions
Adolescent Psychiatry
Title:Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis
Volume: 2 Issue: 2
Author(s): Kate V. Hardy and Rachel Loewy
Affiliation:
Keywords: Adolescents, clinical high risk, cognitive behavioral therapy, psychosis, psychosocial interventions
Abstract: Cognitive Behavioral Therapy (CBT) is an established adjunctive treatment for schizophrenia with a growing evidence base. More recently, CBT has been applied to individuals identified as being at risk for developing psychosis in an attempt to delay or prevent a transition to psychosis, to reduce symptoms and improve functioning. CBT has also been employed effectively with adolescents in the treatment of depression, post traumatic stress disorder (PTSD), anxiety disorders and eating disorders. This paper reviews the evidence for the use of CBT with the clinical high risk for psychosis population and addresses adaptations to the approach for use specifically with adolescents.
Export Options
About this article
Cite this article as:
Hardy Kate V. and Loewy Rachel, Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis , Adolescent Psychiatry 2012; 2 (2) . https://dx.doi.org/10.2174/2210676611202020172
DOI https://dx.doi.org/10.2174/2210676611202020172 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry MicroRNAs as Cancer Biomarkers
MicroRNA A State-of-the-art Review and Prospective Therapeutic Applications of Prenyl Flavonoids as Chemosensitizers against Antifungal Multidrug Resistance in <i>Candida albicans</i>
Current Medicinal Chemistry The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets S100A8/A9 Proteins in Diseases of the Exocrine Pancreas
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands
Current Drug Targets Inflammatory Aspects of Depression
Inflammation & Allergy - Drug Targets (Discontinued) The Value of Elastosonography in Evaluation of Thyroid Nodules
Recent Patents on Medical Imaging Approach to the Patient with Subclinical Cushing’s Syndrome
Current Pharmaceutical Design The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Current Medicinal Chemistry Strategies to Design Inhibitors of Clostridium Botulinum Neurotoxins
Infectious Disorders - Drug Targets Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Personalized Cancer Treatment)
Current Molecular Pharmacology Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics
Endocrine, Metabolic & Immune Disorders - Drug Targets Controlled-release Particulate Cytokine Adjuvants for Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Riboregulators and Metabolic Disorders: Getting Closer Towards Understanding the Pathogenesis of Diabetes Mellitus?
Current Molecular Medicine Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews ADAM-Integrin Interactions: Potential Integrin Regulated Ectodomain Shedding Activity
Current Pharmaceutical Design Purine Analogues as Kinase Inhibitors: A Review
Recent Patents on Anti-Cancer Drug Discovery